ANI Pharmaceuticals, Inc.

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
61.44 ^USD	+1.02%		-3.52%	+11.43%

02/07	ANI Pharmaceuticals Receives FDA Approval for Naproxen Delayed-Release Tablets	MT
02/07	ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP	CI

ANI Pharmaceuticals Provides Standalone Earnings Guidance for the Year 2021

March 09, 2021 at 07:00 pm IST

ANI Pharmaceuticals provided standalone earnings guidance for the year 2021. For the year, the company expects net revenues to be in the range of $207 million to $218 million.

Latest news about ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Receives FDA Approval for Naproxen Delayed-Release Tablets	02/07	MT
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP	02/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Growth Index	01/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Index	01/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Index	01/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Growth Index	01/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Value Index	01/07	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index	01/07	CI
HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $94 From $87, Maintains Buy Rating	26/06	MT
Top Midday Gainers	24/06	MT
Sector Update: Health Care Stocks Advance Premarket Monday	24/06	MT
Sector Update: Health Care	24/06	MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data	24/06	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Amid Uncertainty Ahead of Key Inflation Data	24/06	MT
Transcript : Alimera Sciences, Inc., ANI Pharmaceuticals, Inc. - M&A Call	24/06
Top Premarket Gainers	24/06	MT
ANI Pharmaceuticals to Acquire Alimera Sciences in $381 Million Deal	24/06	MT
ANI Pharmaceuticals, Inc. signed a definitive agreement to acquire Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.	24/06	CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,817,663, According to a Recent SEC Filing	21/06	MT
Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing	06/06	MT
ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing	05/06	MT
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing	22/05	MT
ANI Pharmaceuticals Launches Kionex Suspension	20/05	MT
ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension	20/05	CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing	17/05	MT

Chart ANI Pharmaceuticals, Inc.

Duration

Period

More charts

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ANI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

61.44 USD

Average target price

83 USD

Spread / Average Target

+35.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANI PHARMACEUTICALS, INC.	+11.43%	1.19B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals

ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Pharmaceuticals

ANI Pharmaceuticals Provides Standalone Earnings Guidance for the Year 2021

Latest news about ANI Pharmaceuticals, Inc.

Chart ANI Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Ratings for ANI Pharmaceuticals, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals